BARICADE-PRESERVE Trial
Phase 3
300
about 2.3 years
1–35
5 sites in CO, FL, PA +2
About this study
Researchers are testing whether baricitinib can help preserve beta cell function in people newly diagnosed with type 1 diabetes. The trial will last about 60 weeks.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Baricitinib
- 2.Take Placebo
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
baricitinib
oral (Oral Tablet)
Primary: Change from Baseline in C-peptide Area Under the Curve (AUC)
Secondary: Change from Baseline in Fasting C-Peptide, Change from Baseline in Height, Change from Baseline in Hemoglobin A1c (HbA1c), Change from Baseline in Matsuda Index, Change from Baseline in Mean Total Daily Insulin Dose, Change from Baseline in Number of Manual Insulin Boluses, Change from Baseline in Short Form 36 Version 2 Health Survey, Acute (SF-36v2), Pharmacokinetics (PK): Maximum Concentration (Cmax) of Baricitinib
Endocrinology